Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
-
Publication number: 20120087911Abstract: This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.Type: ApplicationFiled: November 29, 2011Publication date: April 12, 2012Applicant: RSR LIMITEDInventors: JANE SANDERS, JADWIGA FURMANIAK, BARNARD REES SMITH
-
Publication number: 20120087921Abstract: Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.Type: ApplicationFiled: June 15, 2010Publication date: April 12, 2012Applicant: Biokine Therapeutics Ltd.Inventors: Michal Abraham, Orly Eizenberg, Amnon Peled
-
Patent number: 8153135Abstract: Disclosed is a method of producing a polysaccharide-polypeptide conjugate by reacting a polysaccharide with a polypeptide which contains at least one free amino group, wherein a polysaccharide carrier comprising vicinal hydroxyl groups is oxidized under ring opening to create vicinal aldehyde groups and is reacted with one or more base-instable antigenic polypeptide(s) containing at least one free amino group, the polypeptide(s) being bound directly to the polysaccharide carrier via at least one azomethine bond.Type: GrantFiled: September 13, 2005Date of Patent: April 10, 2012Inventors: Hans Loibner, Helmut Eckert
-
Patent number: 8153768Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.Type: GrantFiled: May 2, 2003Date of Patent: April 10, 2012Assignee: Wyeth Holdings CorporationInventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
-
Publication number: 20120084871Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.Type: ApplicationFiled: February 14, 2011Publication date: April 5, 2012Applicant: Schering CorporationInventors: Scott Altmann, Xiaorui Yao, Kim Anne O'Neill, Brian E. Hawes
-
Publication number: 20120077731Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, 1L-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: ApplicationFiled: April 12, 2010Publication date: March 29, 2012Applicant: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
-
Publication number: 20120076833Abstract: A coating for a surface of a surgical implant, the coating including a binding protein for capturing cells to the surface via a bi-functional linker molecule. The linker can have a first functional group (such as a trichlorosilyl group) for covalently linking to the surface, and a second functional group (such as a benzothiosulfonate group) for covalently linking to the binding protein. One exemplary linker molecule is S-(11-trichlorosilyl-undecenyl)benzenethiosulfonate. The coating may be a self-assembled monolayer and may also include a spacer molecule, which can be unreactive with the binding protein. The target cells may be endothelial stem cells (such as endothelial progenitor cells). The binding protein may be an antibody, antibody fragment or non-antibody derived antigen binding molecule. The binding protein may bind a cell surface marker specific to target cell type. Coated surgical implants, and methods of forming such a coating are also contemplated.Type: ApplicationFiled: September 12, 2011Publication date: March 29, 2012Applicant: ECONOUS SYSTEMS INC.Inventors: Michael Thompson, Pasquale Benvenuto, Christophe Blaszykowski
-
Patent number: 8143380Abstract: The invention relates to compounds that exhibit improved bioefficacy in multidose administration. More specifically, the invention relates to polypeptides or peptides modified to include an antibody Fc region and one or more water soluble polymers.Type: GrantFiled: July 8, 2005Date of Patent: March 27, 2012Assignee: Amgen Inc.Inventors: Kenneth W. Walker, Olaf B. Kinstler, Karen C. Sitney
-
Patent number: 8142784Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.Type: GrantFiled: December 2, 2008Date of Patent: March 27, 2012Assignee: Genentech, Inc.Inventors: Allen J. Ebens, Jr., Frederic S. Jacobson, Paul Polakis, Ralph H. Schwall, Mark X. Sliwkowski, Susan D. Spencer
-
Publication number: 20120071635Abstract: Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding the clusterin.Type: ApplicationFiled: October 7, 2011Publication date: March 22, 2012Applicant: National Research Council of CanadaInventors: Maureen D. O'Connor-McCourt, Christiane Cantin, Anne E.G. Lenferink
-
Publication number: 20120070440Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.Type: ApplicationFiled: July 1, 2011Publication date: March 22, 2012Applicant: ABBOTT BIOTHERAPEUTICS CORP.Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
-
Patent number: 8138315Abstract: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including ?v?1, ?v?3 ?v?5, ?v?6, or ?v?8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab? fragment, a scFv, or the like. Binding of the immunoliposome to ?v-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.Type: GrantFiled: May 11, 2011Date of Patent: March 20, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Joshua Goldstein, Allen Magill, Deepak Saini, Linda A. Snyder, Raymond Sweet, Steve P. Weng
-
Publication number: 20120064097Abstract: We provide monoclonal antibodies against interleukin-1? and tumor necrosis factor-? that remain biologically active in vitro when conjugated to high molecular weight polysaccharides. We report enhanced binding of these cytokines when their monoclonal antibodies are conjugated to alginate compared to non-conjugated monoclonal antibodies. In cell assays, polysaccharide-antibody constructs of the invention inhibited cytokine signaling to comparable levels as that of unmodified antibodies. Conjugation of cytokine-neutralizing antibodies to high molecular weight polymers enhances the affinities cytokine-binding moieties used as anti-inflammatory therapeutics.Type: ApplicationFiled: July 20, 2011Publication date: March 15, 2012Inventors: Newell R. Washburn, Liang Tso Sun
-
Publication number: 20120063954Abstract: The invention relates to a device and a method for depletion of hepcidin from blood for treatment of iron deficiency, in particular in anemic patients suffering from chronic renal failure, with the goal of increasing the availability of iron in the body and thus improving the treatment of the anemia. The hepcidin adsorbent comprises a matrix and a hepcidin-binding ligand covalently bonded to the matrix with an affinity having a dissociation constant KD of less than 200 nM.Type: ApplicationFiled: July 15, 2010Publication date: March 15, 2012Inventors: Jutta Passlick-Deetjen, Wolfgang Hofmann
-
Publication number: 20120058131Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development.Type: ApplicationFiled: January 21, 2010Publication date: March 8, 2012Applicant: OXFORD BIOTHERAPEUTICS LTDInventor: Christian Rohlff
-
Publication number: 20120058117Abstract: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occurring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential.Type: ApplicationFiled: June 22, 2011Publication date: March 8, 2012Applicants: MEDAREX, INC., TUFTS UNIVERSITYInventors: Christine Margarete UNGER, Gerald BESTE, Carolin ZEHETMEIER, Blanca LAIN, Claudia TORELLA, Jens NIEWĂ–HNER, Daniel G. JAY, Brenda K. EUSTACE, Roland KNAUER, Kristian Hobold JENSEN
-
Publication number: 20120058476Abstract: The invention provides a novel method of labeling oligonucleotides, with reporter moieties, including but not limited to, quenchers, fluorophores, biotin, digoxigenin, peptides and proteins. In addition, this invention provides a method of detecting hybridization of oligonucleotides. This invention also provides novel azo quenchers having the general formula shown below. The invention further provides compositions comprising labeled oligonucleotides and solid supports. The invention also provides kits comprising at least one composition of the present invention.Type: ApplicationFiled: May 5, 2010Publication date: March 8, 2012Inventors: Andrei Laikhter, Suresh C. Srivastava, Naveen P. Srivastava
-
Publication number: 20120058051Abstract: The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression.Type: ApplicationFiled: April 23, 2010Publication date: March 8, 2012Applicant: THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Christoph Rader, Sivasubramanian Baskar
-
Publication number: 20120058135Abstract: This invention relates to the identification and characterization of racemases and definition of protein signatures of these racemases. More particularly, this invention relates to the identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs and more specifically SEQ ID NOS: 1-4. This invention also relates to antibodies specific for the peptides and to immune complexes of these antibodies with the peptides. Further, the invention relates to methods and kits for detecting racemases using the nucleic acid molecules of the invention, as well as the peptides consisting of the motifs and antibodies to these peptides.Type: ApplicationFiled: September 7, 2010Publication date: March 8, 2012Inventors: Paola Minoprio, Nathalie Chamond, Wim Degrave, Armand Berneman
-
Patent number: 8128926Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.Type: GrantFiled: March 24, 2009Date of Patent: March 6, 2012Assignee: Biogen Idec MA Inc.Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber, Steven D. Miklasz, Christilyn Graff
-
Patent number: 8129502Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: GrantFiled: November 13, 2007Date of Patent: March 6, 2012Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto
-
Patent number: 8129517Abstract: The disclosed invention pertains to improved oligonucleotide manufacturing methods, including novel support compositions that are optionally labeled, their methods of preparation and use. The compositions and methods are particularly well suited for high throughput oligonucleotide manufacturing in that the automated support recognition facilitates loading of the wells with the proper supports. In addition, the labeled supports can be used to confirm that each well of a multi-well plate, such as a 96 or 384 well plate, was properly loaded.Type: GrantFiled: May 21, 2007Date of Patent: March 6, 2012Assignee: Integrated DNA Technologies, Inc.Inventors: Yakov A. Letuchy, William E. Martin, David W. Muller, Shawn Allen, Shawn P. Walsh
-
Patent number: 8129508Abstract: The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step.Type: GrantFiled: March 21, 2006Date of Patent: March 6, 2012Assignee: Medarex, Inc.Inventors: Alahari Arunakumari, Gisela Maria Marques Ferreira
-
Publication number: 20120052513Abstract: The present technology relates gold sub-nanoclusters comprising a gold core and one or more thiolates bound to the gold core, wherein the gold core consists essentially of 23 gold atoms. Methods of preparing and using such sub-nanoclusters are also provided.Type: ApplicationFiled: August 24, 2010Publication date: March 1, 2012Inventors: Pradeep THALAPPIL, Madathumpady Abubaker Habeeb Muhammed
-
Publication number: 20120052042Abstract: The present disclosure relates to amphiphilic compounds, self assembling compositions formed from the amphiphilic compounds and methods of making such compositions.Type: ApplicationFiled: February 22, 2010Publication date: March 1, 2012Inventors: SĂ©bastien Ladet, Philippe Gravagna
-
Publication number: 20120052515Abstract: Compositions and methods for providing antibodies having noncovalent, self-binding properties are disclosed. Such autophilic antibodies can bind cellular receptors to promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with debilitating or life-threatening diseases. Representative diseases targeted by the autophilic antibodies are lymphomas, breast cancers, colon cancers, and melanomas. Autoimmune disorders, Alzheimer's disease, and other neuro-degenerative conditions, as well as graft or transplant rejection, are among other treatable conditions.Type: ApplicationFiled: August 23, 2011Publication date: March 1, 2012Inventors: Heinz Kohler, Alton C. Morgan, JR.
-
Publication number: 20120052068Abstract: Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and methods of making and using the antibodies are also disclosed.Type: ApplicationFiled: August 23, 2011Publication date: March 1, 2012Applicant: InNexus Biotechnology International LimitedInventors: Heinz Kohler, Sybille Muller, Alton C. Morgan
-
Publication number: 20120052007Abstract: The invention provides SPARC binding antibodies that have high affinity to SPARC, particularly plasma SPARC, and methods of using such antibodies in treating conditions including cancer.Type: ApplicationFiled: June 3, 2011Publication date: March 1, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Vuong Trieu, Xiping Liu, Neil Desai
-
Patent number: 8124738Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.Type: GrantFiled: September 26, 2006Date of Patent: February 28, 2012Assignee: Medarex, Inc.Inventors: Jonathan Alexander Terret, Li-sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
-
Publication number: 20120040366Abstract: Embodiments of the present invention generally related to methods and compositions for diagnosing or predicting a genetic disorder. In certain embodiments, the methods may include use of rapid and inexpensive assay systems. Other embodiments concern novel mutation specific peptides associated with BRCA1 or BRCA2. In yet other embodiments, haploid cells are used to diagnose a genetic disorder in a subject.Type: ApplicationFiled: February 10, 2010Publication date: February 16, 2012Applicant: Tissue Genetics, Inc.Inventors: Jeffrey Holt, Kimberly A. Gibson
-
Publication number: 20120035344Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: ApplicationFiled: July 29, 2011Publication date: February 9, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Andreas Ivens, Peter Turecek, Oliver Zoechling
-
Publication number: 20120034231Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: March 29, 2010Publication date: February 9, 2012Applicant: NOVARTIS AGInventors: Michael Bardroff, José M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
-
Publication number: 20120035346Abstract: Dyes and photoluminescent compounds based on polymethine dyes that contain at least one alkyl-phosphonate or substituted alkyl-phosphonate group, including the synthetic precursors, methods of synthesis, and applications thereof. Certain embodiments include heterocyclic ring systems and polymethine linkage are selected such that the resulting polymethine dye is a cyanine dye, a merocyanine dye, or a styryl dye.Type: ApplicationFiled: January 15, 2010Publication date: February 9, 2012Inventors: Ewald A. Terpetschnig, Leonid D. Patsenker, Larysa Markova, Iryna A. Fedyunyaeva, Olga S. Kolosova, Sergiy Starko, Anatoliy Tatarets
-
Publication number: 20120034168Abstract: An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.Type: ApplicationFiled: April 22, 2009Publication date: February 9, 2012Applicants: Fondazione IRCCS "Istituto Nazionale dei Tumori", Universita' degli Studi di VeronaInventors: Marco Colombatti, Giulio Fracasso, Sara Cingarlini, Silvana Canevari, Mariangela Figini
-
Publication number: 20120027814Abstract: A method for bonding a polymeric fiber to tissue is provided which includes providing a polymeric fiber having a plurality of tissue reactive members linked to a surface of the fiber via a specific binding pair, and contacting the polymeric fiber to biological tissue, to covalently bond the fiber to the tissue.Type: ApplicationFiled: July 27, 2011Publication date: February 2, 2012Inventor: SĂ©bastien Ladet
-
Publication number: 20120027843Abstract: A complex essentially comprising a protein having an action of binding to a membrane-bound HB-EGF to promote the uptake of the membrane-bound HB-EGF by cells, and a carrier.Type: ApplicationFiled: February 3, 2010Publication date: February 2, 2012Inventors: Tetsuo Minamino, Eisuke Mekada, Asai Tomohiro, Seiji Takashima, Yoshihiro Asano
-
Patent number: 8105789Abstract: A compound capable of specifically binding to pathogen EF-1? but not host EF-1?, wherein the compound binds to any part of an amino acid sequence having at least 70% sequence identity to amino acids 240-230 of SEQ ID NO:22.Type: GrantFiled: June 30, 2009Date of Patent: January 31, 2012Assignee: The University of British ColumbiaInventors: Neil E. Reiner, Artem Tcherkassov, Devki Nandan
-
Publication number: 20120020986Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.Type: ApplicationFiled: October 11, 2011Publication date: January 26, 2012Applicant: KaloBios Pharmaceuticals, Inc.Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
-
Publication number: 20120020960Abstract: Compositions and methods for an immunotherapeutic approach for human breast cancer is provided herein. Any antagonist of thymic stromal lymphopoietin (TSLP) and/or OX40L to inhibit tumor development and IL-13 secretion by blocking the upregulation of OX40L by DCs exposed to breast cancer, thereby blocking their capacity to generate inflammatory IL-13+TNF?+IL-10negCD4+ T cells (Th2 cells). Thus, TSLP, and/or down-stream pathways, represent novel potential therapeutic targets against human breast cancer.Type: ApplicationFiled: July 22, 2011Publication date: January 26, 2012Applicant: Baylor Research InstituteInventors: Anna Karolina Palucka, Jacques F. Banchereau
-
Publication number: 20120020990Abstract: Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: ApplicationFiled: July 25, 2011Publication date: January 26, 2012Applicant: Schering CorporationInventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips, JR.
-
Patent number: 8101728Abstract: The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy.Type: GrantFiled: April 21, 2006Date of Patent: January 24, 2012Assignee: Danisco US Inc.Inventors: Judith A. Fox, M. Harunur Rashid, Martin Roberge, Volker Schellenberger
-
Publication number: 20120014873Abstract: A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. X may be cleaved extracellularly or intracellularly. The molecules of the present invention may be linear, cyclic, branched, or have a mixed structure.Type: ApplicationFiled: June 7, 2011Publication date: January 19, 2012Applicant: The Regents of the University of CaliforniaInventors: Tao Jiang, Emilia S. Olson, Michael Whitney, Roger Y. Tsien
-
Publication number: 20120014964Abstract: Present inventions demonstrates that alpha synuclein toxicity such as ?-synuclein mediated cell death, alpha synuclein induced reactive oxygen species (ROS) in a cell requires the proapoptotic endonuclease G and that the deletion of the endonuclease G or suppressing of the endonuclease G apoptotic pathway attenuates or counteracts such alpha synuclein toxicity. The present invention compositions and methods for inhibition of ?-synuclein toxicity. The inhibiting ?-synuclein toxicity can be used in methods of treatment of synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atrophy (MSA) and the manufacture of medicaments for such treatment.Type: ApplicationFiled: August 7, 2008Publication date: January 19, 2012Inventors: Veerle Baekelandt, Sabrina Buettner, Frank Madeo, Joris Winderickx
-
Publication number: 20120014952Abstract: Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.Type: ApplicationFiled: June 16, 2011Publication date: January 19, 2012Applicants: The Regents of the University of Colorado, MUSC Foundation for Research DevelopmentInventors: Stephen Tomlinson, V. Michael Holers
-
Publication number: 20120014975Abstract: The invention relates to modified single domain antigen binding molecules, e.g., SDAB molecules, in particular TNF?-binding SDAB molecules. Method of preparing, and using the modified single domain antigen binding molecules described herein, to treat, e.g., TNF?-associated disorders, are also disclosed.Type: ApplicationFiled: July 14, 2011Publication date: January 19, 2012Applicant: Wyeth LLCInventors: Martin Hegen, Stephane Hubert Olland, Yulia Vugmeyster, Xin Xu
-
Publication number: 20120016109Abstract: The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-?36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.Type: ApplicationFiled: July 6, 2011Publication date: January 19, 2012Applicant: CREIGHTON UNIVERSITYInventor: Zhao Yi Wang
-
Patent number: 8097703Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.Type: GrantFiled: June 20, 2006Date of Patent: January 17, 2012Assignee: Medarex, Inc.Inventors: Chetana Rao-Naik, David John King, Jie Liu, Haichun Huang, David B. Passmore, Alasdair Fraser Bell, Josephine M. Cardarelli, Chin Pan, To Uyen Thi Do, Sharline Chen, Dawn M. Tanamachi
-
Publication number: 20120009178Abstract: Anti-Tweak antibodies are described.Type: ApplicationFiled: September 9, 2011Publication date: January 12, 2012Inventors: Linda C. Burkly, Ellen Garber, Alexey Lugovskoy
-
Publication number: 20120009621Abstract: The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified.Type: ApplicationFiled: March 28, 2011Publication date: January 12, 2012Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Motoo YAMASAKI, Yasuhisa SHIRAISHI
-
Publication number: 20120009209Abstract: Peptide sequences that specifically bind infectious prion protein for the generation of antibodies and therapeutic agents are disclosed herein.Type: ApplicationFiled: June 9, 2011Publication date: January 12, 2012Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The United States of America as represented by the Secretary of AgricultureInventors: Robert M. Hnasko, Larry H. Stanker, Stanley B. Prusiner